✦ LIBER ✦

Maintenance of Clinical Efficacy After Dose Reduction of Ixabepilone Plus Capecitabine in Patients With Anthracycline- and Taxane-Resistant Metastatic Breast Cancer: A Retrospective Analysis of Pooled Data From 2 Phase III Randomized Clinical Trials

✍ Scribed by Vicente Valero; Eduard Vrdoljak; Binghe Xu; Eva Thomas; Henry Gómez; Alexey Manikhas; Carlos Medina; Rubi Khaw Li; Jungsil Ro; Linda Bosserman; Linda Vahdat; Pralay Mukhopadhyay; Diane Opatt; Joseph A. Sparano

Book ID: 118430391
Publisher: CIG Media Group, LP.
Year: 2012
Tongue: English
Weight: 405 KB
Volume: 12
Category: Article
ISSN: 1526-8209
DOI: 10.1016/j.clbc.2012.03.013

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Ixabepilone plus capecitabine in metasta

Ixabepilone plus capecitabine in metastatic breast cancer patients with reduced performance status previously treated with anthracyclines and taxanes: a pooled analysis by performance status of efficacy and safety data from 2 phase III studies

✍ Henri Roché; Pierfranco Conte; Edith A. Perez; Joseph A. Sparano; Binghe Xu; Jac 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 378 KB

Ixabepilone plus capecitabine in advance

Ixabepilone plus capecitabine in advanced breast cancer patients with early relapse after adjuvant anthracyclines and taxanes: A pooled subset analysis of two phase III studies

✍ Jacek Jassem; Luis Fein; Mark Karwal; Mario Campone; Ronald Peck; Valerie Poular 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 383 KB

Antiemetic efficacy of the neurokinin-1

Antiemetic efficacy of the neurokinin-1 antagonist, aprepitant, plus a 5HT3 antagonist and a corticosteroid in patients receiving anthracyclines or cyclophosphamide in addition to high-dose cisplatin : Analysis of combined data from two phase III randomized clinical trials

✍ Richard J. Gralla; Ronald de Wit; Jorn Herrstedt; Alexandra D. Carides; Juliana 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 106 KB

Evaluating health-related quality-of-lif

Evaluating health-related quality-of-life therapeutic effectiveness in a clinical trial with extensive nonignorable missing data and heterogeneous response: results from a phase III randomized trial of gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer

✍ Carol M. Moinpour, Gary W. Donaldson, Astra M. Liepa, Allen S. Melemed, Joyce O’ 📂 Article 📅 2011 🏛 Springer Netherlands 🌐 English ⚖ 392 KB